INKT – mink therapeutics, inc. (US:NASDAQ)

News

MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at Robert W. Baird from $8.00 to $4.00. They now have an "outperform" rating on the stock.
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update [Yahoo! Finance]
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com